Jennifer Champoux - 28 May 2024 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Operating Officer
Signature
/s/ Phil Nickson, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
28 May 2024
Net transactions value
$0
Form type
3
Filing time
05 Jun 2024, 16:05:09 UTC
Next filing
05 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLUE Stock Option (Right to Buy) 28 May 2024 Common Stock 116,120 $6.14 Direct F1
holding GLUE Stock Option (Right to Buy) 28 May 2024 Common Stock 46,000 $13.41 Direct F2
holding GLUE Stock Option (Right to Buy) 28 May 2024 Common Stock 59,000 $7.78 Direct F3
holding GLUE Stock Option (Right to Buy) 28 May 2024 Common Stock 5,000 $6.16 Direct F4
holding GLUE Stock Option (Right to Buy) 28 May 2024 Common Stock 79,000 $5.71 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option vested and became exercisable on March 22, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of this option vested and became exercisable on March 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3 25% of this option vested and became exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F4 25% of this option vested and became exercisable on March 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney